Abstract 470P
Background
Due to its high propensity for metastasis and lack of durable response to therapy, several biomarkers have been studied to help predict outcomes in patients with Small Cell Lung Cancer (SCLC). These biomarkers aid the clinicians in their treatment decisions among these patients. Neuron-specific enolase (NSE), can be used in supporting a diagnosis of SCLC. However, little is known on its prognostic significance due to the limited number of studies conducted. Carcino-embryonic antigen (CEA) can be used in treatment monitoring and prognostication in several cancers. Few studies have been conducted among SCLC patients investigating its prognostic significance. Moreover, no meta-analysis has been conducted on this outcome. Vascular endothelial growth factor (VEGF) plays an important role in the dissemination of malignancy. Although serum VEGF is found many cancer patients, little is known about its prognostic significance among SCLC. Moreover, no meta-analysis has been conducted on this outcome. This study aims to conduct a systematic review and meta-analysis on the prognostic significance of the CEA, NSE and VEGF on SCLC.
Methods
A systematic review was conducted to examine the prognostic significance of three biomarkers in the prognosis of SCLC: CEA, VEGF and NSE. Systematic search was done using Pubmed, Cochraine and EMBASE for articles published until July 1, 2019. Seventeen studies with a total of 3, 973 patients were included in the analysis. The primary outcome of interest was Overall Survival in SCLC. Data was summarized using RevMan 5.3. Preplanned subgroup analysis was done on the type of study and the statistic used.
Results
High CEA (HR 1.28 95%CI 1.10-1.50, p < 0.001, I2 45%) and VEGF (HR 1.84 CI 1.21-2.78 p = 0.004, I2 52%) were both associated with poor overall survival. NSE was associated with poor overall survival based on pooled retrospective studies (HR 1.42 CI 1.22-1.67, p < 0.00001, I2 34%) and prospective studies (RR 1.68 CI 1.40-2.02, p < 0.00001, I2 50%). Pooled HR for prospective studies was not significant (HR 2.32 CI 0.96-5.56, p = 0.06, I2 83%).
Conclusions
High NSE, CEA and VEGF may be used as prognostic biomarkers of poor survival in patients with SCLC. Further randomized studies may confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.B.L. Sacdalan: Honoraria (self): Merck. All other authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract